Medicine & Life Sciences
dinaciclib
100%
Hodgkin Disease
64%
Cyclin-Dependent Kinases
53%
Lymphoma
48%
Survival
31%
Progression-Free Survival
31%
Non-Hodgkin's Lymphoma
30%
Therapeutics
29%
Burkitt Lymphoma
28%
Non-Small Cell Lung Carcinoma
26%
T-Cell Lymphoma
25%
Neoplasms
22%
PCI 32765
22%
Hereditary Hemorrhagic Telangiectasia
21%
Drug Therapy
20%
Lymphoma, Large B-Cell, Diffuse
20%
Brentuximab Vedotin
18%
B-Cell Chronic Lymphocytic Leukemia
15%
Immunotherapy
15%
Apoptosis
15%
abexinostat
15%
DNA Sequence Analysis
15%
Hematopoietic Stem Cells
14%
belinostat
13%
Canidae
13%
ixazomib
13%
Multicenter Studies
13%
blinatumomab
13%
Pharmacokinetics
12%
MK 2206
12%
Cyclin-Dependent Kinase 2
12%
Chimeric Antigen Receptors
12%
Clinical Studies
12%
andrographolide
11%
Andrographis
11%
Aprepitant
11%
Transplants
10%
Bispecific Antibodies
10%
Ipilimumab
10%
Cohort Studies
10%
Nivolumab
10%
Cell- and Tissue-Based Therapy
10%
Diterpenes
10%
Fatty Acid Synthases
9%
Tumor Burden
9%
Bevacizumab
9%
Lactones
9%
Erlotinib Hydrochloride
9%
Glutens
9%
Hematopoietic Stem Cell Transplantation
9%
Cell Line
9%
Safety
9%
Bortezomib
9%
Phosphogluconate Dehydrogenase
9%
Malignant Mesothelioma
9%
Transitional Cell Carcinoma
8%
Heterografts
8%
Insurance Coverage
8%
Clinical Trials
8%
Caspases
8%
Stem Cell Transplantation
8%
Geriatrics
8%
Homologous Transplantation
8%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8%
Cone-Beam Computed Tomography
8%
Radiosurgery
8%
Recurrence
8%
Mutation
8%
Organ Transplantation
8%
Transplantation
8%
Graft vs Host Disease
7%
Radiotherapy
7%
Reactive Oxygen Species
7%
Leukemia
7%
Central Nervous System
7%
Standard of Care
7%
Rituximab
7%
Tumor Lysis Syndrome
7%
Names
7%
Pancreatic Neoplasms
7%
Natural Killer Cells
6%
Human Influenza
6%
Survival Rate
6%
Hemorrhage
6%
Bleomycin
6%
Geriatric Assessment
6%
T-Lymphocytes
6%
Multivariate Analysis
6%
Nucleotides
6%
Vaccination
6%
Urinary Bladder
5%
Lung Neoplasms
5%
Acute Coronary Syndrome
5%
Kinetics
5%
Dacarbazine
5%
Activities of Daily Living
5%
Heart Failure
5%